Alkermes (ALKS) Cash & Current Investments (2010 - 2026)
Alkermes' (ALKS) quarterly Cash & Current Investments came in at $511.9 million in Q1 2026, down 42.1% year-on-year from $884.0 million in Q1 2025, and down 54.29% on a QoQ basis from $1.1 billion in Q4 2025.
Alkermes (ALKS) Cash & Current Investments (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Cash & Current Investments data on file, last reported at $511.9 million in Q1 2026.
- On a quarterly basis, Cash & Current Investments fell 42.1% year-over-year to $511.9 million in Q1 2026; TTM through Mar 2026 was $511.9 million, a 42.1% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 48.97% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $511.9 million, down from $1.1 billion in the prior quarter.
- Over the last five years, Cash & Current Investments for ALKS reached as high as $1.1 billion in Q4 2025 and fell as low as $511.9 million in Q1 2026.
- Historically, Cash & Current Investments has averaged $783.2 million across 5 years, with a median of $773.5 million in 2023.
- Across the five-year window, Cash & Current Investments jumped 53.25% in 2023 and sank 42.1% in 2026, its largest moves.
- Year by year, Cash & Current Investments stood at $608.5 million in 2022, then grew by 27.12% to $773.5 million in 2023, then declined by 2.82% to $751.7 million in 2024, then jumped by 48.97% to $1.1 billion in 2025, then plunged by 54.29% to $511.9 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $511.9 million in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 2.15 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 511.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 511.86 Mn |
| Dec 31, 2025 | 1.12 Bn |
| Sep 30, 2025 | 1.11 Bn |
| Jun 30, 2025 | 1.02 Bn |
| Mar 31, 2025 | 884.02 Mn |
| Dec 31, 2024 | 751.67 Mn |
| Sep 30, 2024 | 908.86 Mn |
| Jun 30, 2024 | 876.12 Mn |
| Mar 31, 2024 | 745.05 Mn |
| Dec 31, 2023 | 773.49 Mn |
| Sep 30, 2023 | 889.15 Mn |
| Jun 30, 2023 | 829.05 Mn |
| Mar 31, 2023 | 600.46 Mn |
| Dec 31, 2022 | 608.47 Mn |
| Sep 30, 2022 | 580.18 Mn |
| Jun 30, 2022 | 580.97 Mn |
| Mar 31, 2022 | 528.87 Mn |
| Dec 31, 2021 | 536.31 Mn |
| Sep 30, 2021 | 560.30 Mn |
| Jun 30, 2021 | 538.35 Mn |